Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: PDR001
Drug: LAG525
Drug: ACZ885
Drug: LEE011
Drug: INC280

First Posted Date: 2018-04-02

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 196

Registration Number: NCT03484923

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Massachusetts Gen. Hospital CC, Boston, Massachusetts, United States

and more 4 locations

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2018-03-29

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 566

Registration Number: NCT03481634

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2018-03-29

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 360

Registration Number: NCT03481660

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizumab

First Posted Date: 2018-03-23

Last Posted Date: 2024-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT03474965

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Univ of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States

and more 10 locations

Safety Study of LLF580 in Obese Volunteers

Phase 1

Completed

Conditions: Obesity

Interventions: Biological: LLF580
Drug: Placebo

First Posted Date: 2018-03-15

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT03466203

Locations: 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States

Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients

Phase 2

Withdrawn

Conditions: BK Virus Nephropathy

Interventions: Biological: MAU868
Biological: Placebo

First Posted Date: 2018-03-07

Last Posted Date: 2018-12-13

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03456999

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Canakinumab

First Posted Date: 2018-02-27

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1382

Registration Number: NCT03447769

Locations: 🇺🇸
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States
🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Advanced Medical Specialties Drug Ship - 2, Miami, Florida, United States

and more 18 locations

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Phase 4

Completed

Conditions: Psoriasis
Metabolic Syndrome

Interventions: Drug: Secukinumab
Behavioral: Life-style intervention

First Posted Date: 2018-02-22

Last Posted Date: 2023-05-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 781

Registration Number: NCT03440736

Locations: 🇩🇪
Novartis Investigative Site, Wuppertal, Germany

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Alpelisib
Drug: Fulvestrant
Drug: Letrozole

First Posted Date: 2018-02-20

Last Posted Date: 2024-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 287

Registration Number: NCT03439046

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Interventions: Drug: iptacopan
Combination Product: Standard of Care

First Posted Date: 2018-02-20

Last Posted Date: 2024-06-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT03439839

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy